Published in Obstet Gynecol on January 01, 2006
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ (2007) 3.77
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine (2011) 2.43
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19
Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog (2009) 2.08
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Harnessing the immune system to treat cancer. J Clin Invest (2007) 1.57
Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis (2008) 1.35
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis (2009) 1.35
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine (2010) 1.33
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer (2012) 1.23
Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother (2012) 1.18
Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis (2008) 1.12
Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer (2010) 1.09
Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital (2009) 1.05
Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis (2009) 1.05
Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02
Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. J Virol (2007) 1.02
Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol (2011) 1.01
The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis (2010) 1.01
Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis (2014) 1.00
Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99
Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ (2007) 0.98
Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med (2015) 0.98
Oral squamous papilloma and condyloma acuminatum as manifestations of buccal-genital infection by human papillomavirus. Indian J Sex Transm Dis (2009) 0.96
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2007) 0.96
Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J (2008) 0.93
Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol (2009) 0.93
Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations. PLoS One (2012) 0.93
Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf (2015) 0.92
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer (2014) 0.92
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol (2007) 0.92
Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92
Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types. J Infect Dis (2012) 0.91
An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol J (2009) 0.91
Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
The viral etiology of AIDS-associated malignancies. Adv Pharmacol (2008) 0.89
HPV Vaccines: today and in the Future. J Adolesc Health (2008) 0.88
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer (2007) 0.88
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol (2007) 0.87
Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role. Cancer (2008) 0.87
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger. Int J Clin Exp Pathol (2008) 0.86
Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer (2007) 0.85
Genital warts in children: what do they mean? Arch Dis Child (2006) 0.85
Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health (2011) 0.85
HPV-vaccination against cervical carcinoma: will it really work? Med Microbiol Immunol (2007) 0.84
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front Oncol (2013) 0.84
Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiol Drug Saf (2013) 0.84
Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine. Int J Womens Health (2010) 0.84
Wide local excision for Buschke-Löwenstein tumor or circumferential carcinoma in situ. Tech Coloproctol (2011) 0.83
Cancer vaccines in old age. Exp Gerontol (2007) 0.81
Prophylactic HPV vaccines. J Clin Pathol (2007) 0.80
Human papillomavirus disease and vaccines in adolescents. Adolesc Med State Art Rev (2010) 0.80
Survival from cancer of the uterine cervix in England and Wales up to 2001. Br J Cancer (2008) 0.80
Answering human papillomavirus vaccine concerns; a matter of science and time. Infect Agent Cancer (2013) 0.79
HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health (2014) 0.79
Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78
Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother (2016) 0.77
Potential anti-HPV and related cancer agents from marine resources: an overview. Mar Drugs (2014) 0.76
Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PLoS One (2014) 0.75
HPV vaccination: more questions than answers. Obstet Gynecol (2006) 0.75
Human papillomavirus vaccine: a boon or curse. Hum Vaccin Immunother (2014) 0.75
Human papillomavirus-related gynecologic neoplasms: screening and prevention. Rev Obstet Gynecol (2008) 0.75
ART and prejudice. Ulster Med J (2007) 0.75
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline. J Gynecol Oncol (2016) 0.75
Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Hum Vaccin Immunother (2015) 0.75
Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis (2017) 0.75
Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis. Int J Prev Med (2017) 0.75
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol (2003) 7.35
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med (2006) 5.69
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
The epidemiology of human papillomavirus infections. J Clin Virol (2005) 3.63
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis (2008) 3.19
Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis (2004) 3.18
Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med (2008) 2.98
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol (2009) 2.74
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst (2005) 2.60
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol (2008) 2.51
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst (2005) 2.47
Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2008) 2.44
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun (2006) 2.41
Genital human papillomavirus infection in men. Lancet Infect Dis (2006) 2.39
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis (2006) 2.21
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.05
Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis (2002) 1.99
Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol (2002) 1.94
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol (2003) 1.91
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88